Peak-Muscle.com  

Welcome to the Peak-Muscle.com forums.

You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. Come join us in on one of the best online fitness communities. We have 16,000 members that are likeminded towards a fitness, bodybuilding lifestyle. Registration is free and only takes but a few minutes. By joining our free community you will have access to communicate privately with other members (PM), respond to polls, upload content and access many other special features. You will be able to create threads to discuss and or create a fitness regimen. Or just bounce ideas off of some very knowledgeable members. So don't miss out. Registration is fast, simple and absolutely free so please, join our community today!

Register FAQ Members List Calendar Arcade Mark Forums Read
Go Back   Peak-Muscle.com > Bodybuilding and Fitness Discussion > Over 50 and beyond.
User Name
Password

Reply
 
Thread Tools Display Modes
Old 08-19-2021, 12:14 PM   #1
liftsiron
Administrator
 
liftsiron's Avatar
 

Join Date: Nov 2003
Location: Cimmeria
Posts: 18,386
liftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant futureliftsiron has a brilliant future
EMAS position statement: Testosterone replacement therapy in the aging male‏

Volume 84, February 2016, Pages 94-99
Maturitas
EMAS position statement: Testosterone replacement therapy in the aging male‏
Author links open overlay panelChristinaDimopouloua
IulianaCeausubHermanDepyperecIreneLambrinoudakidAl fredMueckeFaustino R.Pérez-LópezfMargaretReesgYvonne T.van der SchouwhLevent M.SenturkiTommasoSimonsinijJohn C.StevensonkPetraStutelDimitrios G.Goulism
https://doi.org/10.1016/j.maturitas.2015.11.003
Get rights and content
Highlights



Late-onset hypogonadism (LOH) represents a common clinical entity among aging males.


Typical sexual symptoms suggestive of androgen deficiency comprise loss of libido, decreased spontaneous erections and erectile dysfunction.


Testosterone replacement therapy (TRT) should be offered to these individuals, only if a combination of testosterone deficiency symptoms and low testosterone is present.


Management of aging men with LOH should include individual evaluation of co-morbidities and careful risk—benefit assessment.


Evidence from large randomized prospective trials regarding beneficial effects and cardiovascular safety of testosterone replacement therapy is needed.

Abstract
Introduction

Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, characterized by the presence of symptoms (most usually of a sexual nature, such as decreased libido, decreased spontaneous erections and erectile dysfunction) and signs, in combination with low serum testosterone concentrations. Whether testosterone replacement therapy (TRT) should be offered to those individuals is still under extensive debate.
Aims

The aim of this position statement is to provide and critically appraise evidence on TRT in the aging male, focusing on pathophysiology and characteristics of LOH, indications for TRT, available therapeutic agents, monitoring and treatment-associated risks.
Materials and methods

Literature review and consensus of expert opinion.
Results and conclusions

Diagnosis and treatment of LOH is justified, if a combination of symptoms of testosterone deficiency and low testosterone is present. Patients receiving TRT could profit with regard to obesity, metabolic syndrome, type 2 diabetes mellitus, sexual function and osteoporosis and should undergo scheduled testing for adverse events regularly. Potential adverse effects of TRT on cardiovascular disease, prostate cancer and sleep apnea are as yet unclear and remain to be investigated in large-scale prospective studies. Management of aging men with LOH should include individual evaluation of co-morbidities and careful risk versus benefit assessment.
__________________
ADMIN/OWNER@Peak-Muscle
liftsiron is online now   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -5. The time now is 05:55 PM.


Powered by: vBulletin Version 3.8.11
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.